
MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
The Regional Account Manager, Carolinas (RAM) is a key field position and will have the opportunity to run their own business within their assigned region. Reporting to the Area Business Director, East, this individual will possess experience in business ownership, leadership, analytics, and the implementation of innovative solutions. The RAM will formulate an effective regional strategy focusing on Geneticist, Endocrinology, and Metabolic Specialist as their core customers. They will be tasked with establishing short- and long-term business tactics. It will be the responsibility of the RAM to identify key priorities within territories and create and implement business plan that is organizationally approved and fully compliant with all laws. The RAM will be accountable for improving diagnosis rates of all on label indications within their region, growing sales, and effectively partnering across the organization to ensure all goals are met.
The successful RAM will have courage, talent and dedication to seek solutions that can make a meaningful impact within territory or broader team. The ideal candidates are detail orientated, self-structured in their approach to their work, with the ability to manage relationships at all levels. The RAM will have proven presentation and partner management skills and thrive in a rapid paced and dynamic environment within a culture that relies on a patient centric and teamwork orientated approach.
You must reside in one of the following states: South NC, SC, GA
JOB FUNCTIONS/RESPONSIBILITIES
QUALIFICATIONS
Education/Experience:
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.